NASDAQ:TECH

Bio-Techne (TECH) Stock Price, News & Analysis

$83.80
+0.97 (+1.17%)
(As of 05/17/2024 ET)
Today's Range
$82.19
$84.61
50-Day Range
$62.12
$84.15
52-Week Range
$51.79
$89.91
Volume
1.37 million shs
Average Volume
1.12 million shs
Market Capitalization
$13.21 billion
P/E Ratio
66.51
Dividend Yield
0.38%
Price Target
$80.50

Bio-Techne MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
3.9% Downside
$80.50 Price Target
Short Interest
Bearish
3.76% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.76
Upright™ Environmental Score
News Sentiment
1.41mentions of Bio-Techne in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$800,592 Sold Last Quarter
Proj. Earnings Growth
16.03%
From $1.56 to $1.81 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.19 out of 5 stars

Medical Sector

140th out of 922 stocks

Biological Products, Except Diagnostic Industry

15th out of 155 stocks

TECH stock logo

About Bio-Techne Stock (NASDAQ:TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Stock Price History

TECH Stock News Headlines

Bio-Techne Corporation (TECH) Declined on Weak Q4 Results
Bio-Techne Corp. Q3 Profit Decreases, but beats estimates
BIO-TECHNE DECLARES DIVIDEND
Bio-Techne earnings preview: what Wall Street is expecting
Bio-Techne In Distribution Agreement With Thermo Fisher Scientific
See More Headlines
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/26 Dividend
2/09/2024
Dividend Payable
2/26/2024
Last Earnings
5/01/2024
Ex-Dividend for 5/24 Dividend
5/10/2024
Today
5/17/2024
Dividend Payable
5/24/2024
Fiscal Year End
6/30/2024
Next Earnings (Estimated)
8/13/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TECH
CUSIP
87837710
Employees
3,050
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$80.50
High Stock Price Target
$95.00
Low Stock Price Target
$65.00
Potential Upside/Downside
-3.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$285.26 million
Pretax Margin
20.13%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$2.53 per share
Book Value
$12.78 per share

Miscellaneous

Free Float
150,572,000
Market Cap
$13.21 billion
Optionable
Optionable
Beta
1.23

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


TECH Stock Analysis - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings
or view top-rated stocks.

What is Bio-Techne's stock price target for 2024?

11 Wall Street analysts have issued twelve-month price targets for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $95.00. On average, they expect the company's share price to reach $80.50 in the next year. This suggests that the stock has a possible downside of 3.9%.
View analysts price targets for TECH
or view top-rated stocks among Wall Street analysts.

How have TECH shares performed in 2024?

Bio-Techne's stock was trading at $77.16 on January 1st, 2024. Since then, TECH shares have increased by 8.6% and is now trading at $83.8050.
View the best growth stocks for 2024 here
.

When is Bio-Techne's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our TECH earnings forecast
.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) released its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The biotechnology company had revenue of $303.43 million for the quarter, compared to the consensus estimate of $292.36 million. Bio-Techne had a trailing twelve-month return on equity of 13.60% and a net margin of 17.59%. The business's quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.47 earnings per share.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Wednesday, May 1st. Shareholders of record on Monday, May 13th will be paid a dividend of $0.08 per share on Friday, May 24th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date is Friday, May 10th.
Read our dividend analysis for TECH
.

Is Bio-Techne a good dividend stock?

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.38%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 25.40%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 17.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?

Bio-Techne shares split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly minted shares were issued to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What is Charles Kummeth's approval rating as Bio-Techne's CEO?

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.62%), Price T Rowe Associates Inc. MD (3.65%), Bamco Inc. NY (3.17%), Bank of New York Mellon Corp (1.82%), Champlain Investment Partners LLC (1.74%) and Brown Capital Management LLC (1.63%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends
.

How do I buy shares of Bio-Techne?

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Bio-Techne have any subsidiaries?
The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
This page (NASDAQ:TECH) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners